



#4 1651
5-4-01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Kay et al.	Examiner:	Unassigned
Serial No.:	09/650,055	Group Art Unit:	1651
Filed:	August 29, 2000	Docket:	1040-5
For:	Composition and Method for Treatment of Conditions Having an Inflammatory Component	Dated:	January 11, 2001

RECEIVED
JAN 19 2001
TECH CENTER 1600/2500

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.
20231 on January 11, 2001*

Dated: 1/11/01 Kathleen A. G.

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Rovati	3,683,076	Aug. 8, 1972
Capozza	3,911,098	Oct. 7, 1975
Prudden	4,006,224	Feb. 1, 1977
Shen	4,228,161	Oct. 14, 1980
Meisner	4,647,453	Mar. 3, 1987

UNITED STATES PATENTS (Continued)

RECEIVED
JAN 19 2001
TECH CENTER 16042000

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Kifune	4,704,268	Nov. 3, 1987
Meisner	4,772,591	Sep. 20, 1988
Henderson	5,364,845	Nov. 15, 1994
Shell	5,582,837	Dec. 10, 1996
Henderson	5,587,363	Dec. 24, 1996
Oshlack et al.	5,681,585	Oct. 28, 1997
Drizen et al.	5,716,631	Feb. 10, 1998
Dunn	5,736,152	Apr. 7, 1998
Florio	5,840,715	Nov. 24, 1998
Burger	5,843,919	Dec. 1, 1998
Vournakis et al.	5,846,952	Dec. 8, 1998
Aoyagi et al.	5,849,336	Dec. 15, 1998
Pinkus	5,855,915	Jan. 5, 1999
Weisman	5,888,514	Mar. 30, 1999
Rose et al.	5,916,565	June 29, 1999
Ashida et al.	5,994,324	Nov. 30, 1999
Drizen et al.	6,007,843	Dec. 28, 1999
Myers et al.	6,020,002	Feb. 1, 2000
Murch et al.	6,046,179	Apr. 4, 2000

NON-PATENT PUBLICATIONS

RECEIVED
JAN 19 2001
TECH CENTER 1800/2000

1. Baron et al., "Glucosamine Induces Insulin Resistance In Vivo By Affecting GLUT 4 Translocation in Skeletal Muscle," *J. Clin. Investigation, Inc.*, 96:2792-2801, (December 1995).
2. McClain et al., "Hexosamines and Insulin Resistance," *Diabetes*, 45:1003-1009, (1996).
3. Talent et al., "Pilot Study of Oral Polymeric N-acetyl-D-glucosamine as a Potential Treatment for Patients with Osteoarthritis (ABSTRACT)," *Clin. Ther.*, 18(6):1184-90, (Nov.-Dec. 1996).
4. Rege et al., "Chitosans as Tableting Excipients for Modified Release Delivery Systems (ABSTRACT)," *Int. J. Pharm*, 181 (1):49-60, (April 20, 1999).

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,



Robert C. Morriss
Registration No.: 42,910
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550

RCM:kd
115934_1.DOC